← Leaderboards
Himisha Beltran
Dana-Farber Cancer Inst
$8,786,271
Attributed
$9,747,098
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,105,867 · 8
By mechanism
P50$13,651,784 · 6
R37$3,532,429 · 1
R01$1,921,654 · 1
Top collaborators
- Steven P. Balk4 shared
- David S. Rickman3 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Qianben Wang$7,988,225
- Matthew Gilbert Oser$2,847,213
- Nathanael Schiander Gray$36,761,550
- Camilla L Christensen$257,380
- Alan David D'andrea$28,094,196
Others in their field
Other Emerging Leaders on “Malignant Neoplasm Of Prostate”
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Greg Yothers · University Of Chicago$35,003,821
- Lynn Briscoe · Leidos Biomedical Research, Inc.$30,044,343
- Leonard Freedmand · Leidos Biomedical Research, Inc.$11,639,100
- John Freymann · Leidos Biomedical Research, Inc.$8,749,308
- Kathleen Nicol · Research Inst Nationwide Children'S Hosp$7,152,405
Research focus
Malignant Neoplasm Of ProstateProgramsAndrogen ReceptorProstateResistanceTumorPhenotypeTargeted TreatmentTherapy ResistantReceptor SignalingDna MethylationNeurosecretory SystemsMolecularMalignant NeoplasmsEpigenetic ProcessMemberDependenceAreaCellsEarly DiagnosisRb1 GeneCancer PatientDna Sequence AlterationResistance Mechanism
Grant awards (27)
DF/HCC Prostate SPORE$2,079,312
P50 · FY2025 · CA · contact PI
"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"$645,518
R01 · FY2025 · CA
Molecular mechanisms underlying lineage plasticity in prostate cancer$601,022
R37 · FY2025 · CA · contact PI
Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate Cancer$345,602
P50 · FY2025 · CA · contact PI
Career Enhancement Program$186,612
P50 · FY2025 · CA · contact PI
DF/HCC Prostate SPORE$163,138
P50 · FY2025 · CA · contact PI
DF/HCC Prostate SPORE$2,393,890
P50 · FY2024 · CA · contact PI
"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"$613,243
R01 · FY2024 · CA
Molecular mechanisms underlying lineage plasticity in prostate cancer$564,876
R37 · FY2024 · CA · contact PI
Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate Cancer$442,125
P50 · FY2024 · CA · contact PI
Career Enhancement Program$237,839
P50 · FY2024 · CA · contact PI
DF/HCC Prostate SPORE$183,437
P50 · FY2024 · CA · contact PI
DF/HCC Prostate SPORE$2,585,567
P50 · FY2023 · CA · contact PI
"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"$662,893
R01 · FY2023 · CA
Molecular mechanisms underlying lineage plasticity in prostate cancer$582,713
R37 · FY2023 · CA · contact PI
Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate Cancer$474,523
P50 · FY2023 · CA · contact PI
Career Enhancement Program$258,162
P50 · FY2023 · CA · contact PI
DF/HCC Prostate SPORE$241,285
P50 · FY2023 · CA · contact PI
Molecular mechanisms underlying lineage plasticity in prostate cancer$594,606
R37 · FY2022 · CA · contact PI
Molecular mechanisms underlying lineage plasticity in prostate cancer$594,606
R37 · FY2021 · CA · contact PI
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer$343,785
P50 · FY2021 · CA · contact PI
Molecular mechanisms underlying lineage plasticity in prostate cancer$594,606
R37 · FY2020 · CA · contact PI
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer$351,178
P50 · FY2020 · CA · contact PI
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer$343,785
P50 · FY2019 · CA · contact PI
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer$369,660
P50 · FY2018 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$2,300,000
P50 · FY2017 · CA · contact PI
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer$351,884
P50 · FY2017 · CA · contact PI